Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tutkimustutkimus siitä, kuinka hyvin konsitsumabi toimii sinulle, jos sinulla on hemofilia A tai B estäjillä tai ilman (Explorer10)

torstai 17. syyskuuta 2026 päivittänyt: Novo Nordisk A/S

Avoin tutkimus, jossa tutkitaan konsitsumabin eston tehoa, turvallisuutta ja farmakokinetiikkaa alle 12-vuotiailla lapsilla, joilla on hemofilia A tai B estäjillä tai ilman

This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.

Participants will have to inject the study medicine every day under the skin with a pen-injector.

The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.

Tutkimuksen yleiskatsaus

Tila

Aktiivinen, ei rekrytointi

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

153

Vaihe

  • Vaihe 3

Laajennettu käyttöoikeus

Ei ole enää käytettävissä kliinisen tutkimuksen ulkopuolella. Katso laajennettu käyttöoikeustietue.

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Algiers, Algeria, 16000
        • Haematology and Blood Bank Department
      • Constantine, Algeria, 25000
        • CHU Constantine BEN BADIS/ Hematology department
      • Banja Luka, Bosnia ja Hertsegovina, 78000
        • University Clinical Center of Republic Srpska (545)
      • Tuzla, Bosnia ja Hertsegovina, 75000
        • University Clinical Centre Tuzla
      • Plovdiv, Bulgaria, 4002
        • UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
      • Sofia, Bulgaria, 1527
        • UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
      • Varna, Bulgaria, 9010
        • UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
      • Barcelona, Espanja, 08035
        • Hospital Vall d'Hebron
      • Madrid, Espanja, 28046
        • Hospital Universitario La Paz
      • Málaga, Espanja, 29009
        • Hospital Regional Universitario de Málaga
    • Murcia
      • El Palmar, Murcia, Espanja, 30120
        • Hospital Virgen de la Arrixaca - Hematología
    • Gauteng
      • Parktown, Johannesburg, Gauteng, Etelä-Afrikka, 2193
        • Charlotte Maxeke Johannesburg Academic Hospital
    • Assam
      • Guwahati, Assam, Intia, 781032
        • Guwahati Medical College
    • Gujarat
      • Surat, Gujarat, Intia, 395002
        • Nirmal Hospital Pvt. Ltd.
    • Maharashtra
      • Kolhāpur, Maharashtra, Intia, 416005
        • SSSH_Dept. of Clinical Haematology & Haemato Oncology
      • Mumbai, Maharashtra, Intia, 400012
        • Seth GS Medical College & KEM Hospital
      • Mumbai, Maharashtra, Intia, 400022
        • K.J Somaiya Hospital and Research Centre
      • Mumbai, Maharashtra, Intia, 400066
        • MCGM - Comprehensive Thalassemia Care
      • Pune, Maharashtra, Intia, 411004
        • Sahyadri Super Speciality Hospital
    • Odisha
      • Cuttack, Odisha, Intia, 753007
        • S.C.B. Medical College
    • Rajasthan
      • Jaipur, Rajasthan, Intia, 302004
        • J K Lon Hospital
    • Uttar Pradesh
      • Noida, Uttar Pradesh, Intia, 201303
        • Post Graduate Institute of Child Health
    • Uttart Pradesh
      • Lucknow, Uttart Pradesh, Intia, 226014
        • SGPGI
      • Catania, Italia, 95123
        • A.O.U policlinico "G. Rodolico-San Marco"
      • Florence, Italia, 50134
        • Dipartimento di Ematologia Univ. Firenze
      • Padova, Italia, 35128
        • Azienda Ospedaliera di Padova _
      • Parma, Italia, 43126
        • Azienda Ospedaliera-Universitaria Parma
      • Kanagawa, Japani, 216-8511
        • St. Marianna University School of Medicine Hospital_Pediatrics
      • Saitama, Japani, 330-8777
        • Saitama Children's Med Centre_Hematology-Oncology
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • BC Children's Hospital
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • McMaster Children's Hospital
      • Athens, Kreikka, GR-11527
        • Aghia Sophia Childrens' Hospital
      • Thessaloniki, Kreikka, GR 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
      • Thessaloniki, Kreikka, 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
      • Beirut, Libanon, 961
        • Saint George Hospital University Medical Center
      • Tripoli, Libanon, 1434
        • Hospital Nini
      • Vilnius, Liettua, LT-08406
        • Centre of Oncology and Hematology, Vilnius University
    • Kuala Lumpur
      • Kampung Baru, Kuala Lumpur, Malesia, 50300
        • Hospital Tunku Azizah
    • Pulau Pinang
      • George Town, Pulau Pinang, Malesia, 10450
        • Hospital Pulau Pinang
    • Sarawak
      • Kuching, Sarawak, Malesia, 93586
        • Sarawak General Hospital
    • Terengganu
      • Kuala Terengganu, Terengganu, Malesia, 20400
        • Hospital Sultanah Nur Zahirah
      • Oslo, Norja, 0372
        • Klinisk forskningspost
      • Skopje, Pohjois-Makedonia, 1000
        • PHI University Clinic for Children's Diseases Skopje
      • Gdansk, Puola, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Lublin, Puola, 20-093
        • Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
      • Warsaw, Puola, 02-091
        • Uniwersyteckie Centrum Kliniczne WUM
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Puola, 50-556
        • Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
      • Chambéry, Ranska, 73000
        • Centre Hospitalier Metropole Savoie
      • Le Kremlin-Bicêtre, Ranska, 94275
        • Ap-Hp-Hopital de Bicetre-1
      • Paris, Ranska, 75015
        • AP-HP-HOPITAL NECKER_Service d'hématologie
      • Bucharest, Romania, 022328
        • Clinic of Haematology, Fundeni Clinical Institute
      • Cluj-Napoca, Romania, 400177
        • Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
      • Oradea, Romania, 410469
        • Spitalul Clinic Judetean De Urgenta Bihor
      • Gothenburg, Ruotsi, 413 46
        • Sahlgrenska US - Koagulationscentrum
      • Bangkok, Thaimaa, 10400
        • Ramathibodi Hospital
      • Bangkok, Thaimaa, 10330
        • King Chulalongkorn Memorial Hospital_Bangkok_0
      • Bangkok, Thaimaa, 10700
        • Siriraj Hospital - Hematology and Oncology
      • Bangkok, Thaimaa, 10330
        • King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
    • Mueang Distirct,
      • Ubon Ratchathani, Mueang Distirct,, Thaimaa, 34000
        • Sunpasitthiprasong Hospital_Pediatrics Department
      • Adana, Turkki (Türkiye), 01130
        • Acibadem Adana Hastanesi
      • Adana, Turkki (Türkiye), 01130
        • Acıbadem Adana Hastanesi-Hematoloji
      • Izmir, Turkki (Türkiye), 35100
        • Ege Universitesi Tip Fakultesi
      • Izmir, Turkki (Türkiye), 35100
        • Ege Üniversitesi Hastanesi- Hematoloji
      • Samsun, Turkki (Türkiye), 55139
        • Ondokuz Mayis University Medical Faculty Ped. Haematology
      • Samsun, Turkki (Türkiye), 55139
        • Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
    • Beşevler/Ankara
      • Ankara, Beşevler/Ankara, Turkki (Türkiye), 06500
        • Gazi University
      • Ankara, Beşevler/Ankara, Turkki (Türkiye), 06500
        • Gazi Üniversitesi Hastanesi- Hematoloji
      • Tallinn, Viro, 13419
        • Tallinn Children's Hospital
      • Birmingham, Yhdistynyt kuningaskunta, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Yhdistynyt kuningaskunta, BS2 8BJ
        • University Hospitals Bristol & Weston NHS Foundation Trust
      • London, Yhdistynyt kuningaskunta, WC1N 3HR
        • Great Ormond Street Hospital for Children
      • London, Yhdistynyt kuningaskunta, SE1 7EH
        • Evelina London Children's Hospital - Haemophilia
    • California
      • San Diego, California, Yhdysvallat, 92123
        • Rady Childrens Hosp San Diego
    • Colorado
      • Aurora, Colorado, Yhdysvallat, 80045
        • University of Colorado Hospital
    • Florida
      • Orlando, Florida, Yhdysvallat, 32806
        • Arnold Palmer Children's Hospital
      • Orlando, Florida, Yhdysvallat, 32827
        • Nemours Child Orlando Hem/Onc.
    • Georgia
      • Augusta, Georgia, Yhdysvallat, 30912
        • Augusta Univ/Childrens Hosp-GA
      • Savannah, Georgia, Yhdysvallat, 31404
        • Memorial Health University Medical Center
    • Illinois
      • Chicago, Illinois, Yhdysvallat, 60611
        • Childrens Hospital of Chicago
    • Indiana
      • Indianapolis, Indiana, Yhdysvallat, 46260
        • Indiana Hemophilia-Thromb Ctr
    • Louisiana
      • New Orleans, Louisiana, Yhdysvallat, 70121
        • Ochsner Clinic Foundation
      • New Orleans, Louisiana, Yhdysvallat, 70118
        • Children's Hosp-New Orleans
    • Missouri
      • Kansas City, Missouri, Yhdysvallat, 64108
        • The Children's Mercy Hospital
    • Nebraska
      • Omaha, Nebraska, Yhdysvallat, 68114
        • Children's Nebraska
    • North Carolina
      • Greenville, North Carolina, Yhdysvallat, 27834
        • ECU Sickle Cell Comp Clinic
    • Ohio
      • Columbus, Ohio, Yhdysvallat, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Yhdysvallat, 19134
        • St Christopher Hosp for Child
    • Tennessee
      • Nashville, Tennessee, Yhdysvallat, 37232
        • Monroe Carell Jr. Children's Hospital at Vanderbilt
    • Texas
      • Fort Worth, Texas, Yhdysvallat, 76104
        • Cook Children's Hospital-Hematology-Oncology
      • Houston, Texas, Yhdysvallat, 77030
        • Texas Children's Hospital_Houston
    • Virginia
      • Charlottesville, Virginia, Yhdysvallat, 22908
        • Pediatrics Hematology/Oncology Clinic Battle Building

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Lapsi
  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

  • Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.

  • For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.

  • For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)

    1. Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    2. Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    3. Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
  • For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)

    1. Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
    2. Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
  • For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.

Exclusion Criteria:

  • Known or suspected hypersensitivity to study intervention or related products.
  • Known inherited or acquired coagulation disorder other than congenital haemophilia.
  • Ongoing or planned Immune Tolerance Induction treatment.
  • History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Concizumab-naïve patients

Concizumab-naïve participants below 12 years of age at the time of consent/assent

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Kokeellinen: Patients coming from compassionate use

Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of patient(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: Week 32

Measured in ng/mL

Week 32
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: Week 32

Measured in nM

Week 32
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: Week 32

Measured in ng/mL

Week 32
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: Prior to the concizumab administration at week 20

Measured in ng/mL

Prior to the concizumab administration at week 20
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
Aikaikkuna: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng*hr/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Opintojohtaja: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Torstai 24. maaliskuuta 2022

Ensisijainen valmistuminen (Todellinen)

Tiistai 21. huhtikuuta 2026

Opintojen valmistuminen (Arvioitu)

Perjantai 2. marraskuuta 2029

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 15. marraskuuta 2021

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 15. marraskuuta 2021

Ensimmäinen Lähetetty (Todellinen)

Perjantai 26. marraskuuta 2021

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 18. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 17. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • NN7415-4616
  • U1111-1247-7330 (Muu tunniste: World Health Organization (WHO))
  • 2020-000504-11 (EudraCT-numero)
  • jRCT2031220097 (Rekisterin tunniste: JAPIC)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa